Electra Therapeutics Prices Upsized $350 Million IPO at $15 Per Share

Key Facts

1Electra Therapeutics priced its upsized initial public offering of 23,333,334 shares at $15.00 per share.

2Gross proceeds from the offering are expected to be approximately $350.0 million before underwriting discounts and expenses.

In a move reflecting sustained investor appetite for the biotechnology sector, Electra Therapeutics has announced the pricing of its upsized initial public offering. According to reports, the company priced 23,333,334 shares of common stock at $15.00 per share. Gross proceeds from the offering are expected to reach approximately $350.0 million before underwriting discounts and estimated expenses.

The company is transitioning to a public entity to fund its clinical-stage biopharmaceutical pipeline, which focuses on precision medicines for immune-mediated diseases and cancer. Per market data and analyst reports, the shares are expected to begin trading on the Nasdaq Global Select Market on September 18, 2026, under the ticker symbol ETRA, with the offering scheduled to close on September 21, 2026.

As of the current market snapshot on September 18, 2026, specific price levels for the new instrument are unavailable until trading commences. Investors should monitor broader market sentiment following recent US data, such as the Michigan Consumer Sentiment which stood at 47.8, as it may influence the volatility of new listings in the healthcare sector.